Psoriasis and erythema nodosum: Two comorbidities of inflammatory bowel diseases

Giornale Italiano di Dermatologia e Venereologia

Volumn 148, Issue 2, 2013, Pages 175-184

  De Simone, C ^a   Sollena, P ^a   Coco, V ^a   Caldarola, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Colitis, ulcerative; Comorbidity; Erythema nodosum; Psoriasis

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; HLA ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; JANUS KINASE 2; MESSENGER RNA; PEROXIREDOXIN 5; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

AUTOIMMUNE THYROIDITIS; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; GENE LOCUS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; INNATE IMMUNITY; KERATINOCYTE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84879021302     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
2. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn's colitis database. Am J Gastroenterol 2006;101:1274-82. (Pubitemid 43833122)
3. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2001;106:110-9.
4. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008;40(Suppl 2):S253-9. (Pubitemid 351878068)
5. Greenstein AJ, Janowiz HD, Sachar DB. The extraintestinal manifestations of crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
6. Roberts N, Bunker C. The gut and the skin. Br J Hosp Med 1993;50:31-9.
7. Georgiou G, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron 2006;1:158-68.
8. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol 2012;3:13.
9. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005:11,7227-36. (Pubitemid 43137668)
10. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982;106:323-30. (Pubitemid 12177002)
11. Hoffmann R, Schieferstein G, Schunter F, Jenss H. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1991;86:787-8.
12. Hughes S, Williams SE, Turnberg LA. Crohn's disease and psoriasis. N Engl J Med 1983;308: 101. (Pubitemid 13221194)
13. Yüksel I, Başar O, Ataseven H, Ertuǧrul I, Arhan M, Ibiş, M et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:546-50.
14. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3. (Pubitemid 20235791)
15. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009;23:561-5.
16. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2012 [Epub ahead of print].
17. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40-6.
18. Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol 2012;26:644-50.
19. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6. (Pubitemid 351252875)
20. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-12.
21. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. (Pubitemid 44871953)
22. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-61. (Pubitemid 351847381)
23. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009;41:1330e4.
24. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
25. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012;90:636-47.
26. Braun-Falco O, Schmoeckel C. The dermal inflammatory reaction in initial psoriatic lesions. Arch Dermatol Res 1977;258:9-16. (Pubitemid 8071666)
27. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205. (Pubitemid 28307304)
28. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol 1990;126:351-5. (Pubitemid 20094675)
29. MacDonald TT, Hutchings P, Choy M, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon gamma production measured at single cells level in normal and inflamed human intestine. Clin Exp Immunol 1991;81:301-5. (Pubitemid 20242538)
30. Wakefield P, James W, Sallaska C, Meltzer M. Tumor necrosis factor. J Am Acad Dermatol 1991;24:675-85.
31. Holtmann MH, Schütz M, Galle PR, Neurath MF. Functional relevance of soluble TNF-alpha, transmembrane TNF-alpha and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases. Z Gastroenterol 2002;40:587-600. (Pubitemid 35021273)
32. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957. (Pubitemid 47300009)
33. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1090-100.
34. Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008;14:5154-61.
35. Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002;282:G1035-44. (Pubitemid 34651610)
36. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 2010;21:435-41.
37. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8.
38. Peyrin-Biroulet L, Loftus Jr EV, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471-8.
39. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36. (Pubitemid 41242675)
40. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007;6:366-72. (Pubitemid 46810396)
41. Iborra M, Beltran B, Bastida G, Aguas M, Nos P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2011,5:157-61.
42. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
43. Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:921-7.
44. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001. (Pubitemid 351990997)
45. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for Interferon-a. J Invest Dermatol 2005;125:14-6.
46. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and non biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513-26.
47. Michaelsson G, Kajermo U, Michaelsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-a in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1243-4. (Pubitemid 41779595)
48. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34. (Pubitemid 37026492)
49. Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A et al. Structural basis for dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010;402:797-812.
50. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
51. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84. (Pubitemid 351671884)
52. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
53. Sandborn WJ, Gasink C, Gao LL, Blank M, Johanns J et al. A multicenter, randomized, doubleblind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the Certifi Trial. Gastroenterology 2011;140:109.
54. US National Institues of Health - 2011. Available at: http://clinical-trials.gov/ct2/results?term=ustekinumab+Crohn%27s+disease
55. Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. Am Fam Physician 2007;75:695-700. (Pubitemid 46397886)
56. Requena L, Requena C. Erythema nodosum. Dermatology Online Journal 2002;8:4.
57. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998:4:142-8. (Pubitemid 128699845)
58. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008:26:265-73. (Pubitemid 351978196)
59. Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006;26:663-8.
60. Veloso FT, Carvalho S, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34. (Pubitemid 26244497)
61. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580-5. (Pubitemid 41297914)
62. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985;80:615-20. (Pubitemid 15040873)
63. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8. (Pubitemid 34977077)
64. van der Velden JJ, van Marion AM, Kremer B, Straetmans JM, Henquet CJ, Frank J. Erythema nodosum as an early sign of Crohn's disease. Int J Dermatol 2007;46(Suppl 3):27-9. (Pubitemid 350020128)
65. Labunski S, Posern G, Ludwig S, Kundt G, Brocker EB, Kunz M. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol 2001;81:18-21.
66. Vanbiervliet G, Anty R, Schneider S, Arab K, Rampal P, Hebuterne X. Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab. Gastroenterol Clin Biol 2002;26:295-7. (Pubitemid 34408024)
67. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003;37:150-4. (Pubitemid 39274541)
68. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-tumour necrosis factor therapy. Acta Gastroenterol Belg 2005;68:376-9. (Pubitemid 41474747)
69. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006;31:823-4. (Pubitemid 44563409)
70. Rosen T, Martinelli P. Erythema nodosum associated with infliximab therapy. Dermatol Online J. 2008;14:3.
71. Delle Sedie A, Bazzichi L, Bombardiert S, Riente L. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol 2007;36:403-4. (Pubitemid 350034813)
72. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005;19:603-6. (Pubitemid 41723284)
73. Bruun JM, Nielsen CB, Pedersen SB, Flyvbjerg A, Richelsen B. Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. Horm Metab Res 2003;35:142-6. (Pubitemid 36577854)
74. Deb S, Amin S, Imir AG, Yilmaz MB, Suzuki T, Sasano H et al. Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts. J Clin Endocrinol Metab 2004;89:4018-24. (Pubitemid 39071509)
75. Verdú EF, Deng Y, Bercik P, Collins SM. Modulatory effects of estrogen in two murine models of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2002;283:G27-36. (Pubitemid 34666159)